"For years, we've debated over the best way to restore vessel function to patients with coronary artery disease," said Charles Simonton, M.D., chief medical officer of Abbott's vascular business. "It's important to weigh the benefits and risk of any treatment, and these data provide confidence that XIENCE can be considered as a potential option for many types of patients with coronary artery disease, including those with left-main disease."
About coronary artery disease:
Coronary artery disease is caused when cholesterol and fat build up inside the arteries that supply oxygen-rich blood to the heart. If blood flow to the heart is reduced or blocked, a person can experience chest discomfort (angina) or heart attack.1 Left-main coronary artery disease affects the artery that feeds blood to the left side of the heart, and is associated with increased chance of heart attack and poorer clinical outcomes compared with other types of coronary artery disease.
Ad Statistics
Times Displayed: 110567
Times Visited: 6658 MIT labs, experts in Multi-Vendor component level repair of: MRI Coils, RF amplifiers, Gradient Amplifiers Contrast Media Injectors. System repairs, sub-assembly repairs, component level repairs, refurbish/calibrate. info@mitlabsusa.com/+1 (305) 470-8013
About the study:
The quality-of-life analysis was conducted based on data from the XIENCE EXCEL study (n=1,905), an international, open-label, multicenter randomized trial that compared the safety and efficacy of percutaneous coronary intervention with XIENCE versus surgery known as coronary artery bypass grafting (CABG) in patients with left main coronary artery disease. Quality-of-life was assessed at baseline, one month, one year and three years using the Seattle Angina Questionnaire (SAQ), the 12-item Short Form Health Survey (SF-12), the Rose Dyspnea Scale (RDS), the Patient Health Questionnaire (PHQ-8), and the EuroQOL (EQ-5D).
About XIENCE:
The XIENCE family of everolimus-eluting coronary stent systems are indicated for improving coronary luminal diameter in patients, including people with diabetes mellitus, de novo chronic total coronary occlusions, and people with symptomatic heart disease due to de novo native coronary artery lesions. XIENCE has an unprecedented safety profile, with consistent low rates of stent thrombosis, even in complex cases.6,7 A special coating on XIENCE interacts with proteins in the blood to reduce the risk for blood clots in the stent. For more information visit www.XienceProof.com/US.
For U.S. Important Safety Information, visit: https://vascular.abbott.com/Xience-Stent-Safety.html#isi
About Abbott:
At Abbott, we're committed to helping you live your best possible life through the power of health. For more than 125 years, we've brought new products and technologies to the world -- in nutrition, diagnostics, medical devices and branded generic pharmaceuticals -- that create more possibilities for more people at all stages of life. Today, 94,000 of us are working to help people live not just longer, but better, in the more than 150 countries we serve.
